



## Miniaturized Experimental Toolbox for -Transaminase Technology (BIOINTENSE)

**Pereira Rosinha, Ines; Ringborg, Rolf Hoffmeyer; Heintz, Søren; Tufvesson, Pär; Schürmann, Martin; Panella, Lavinia; Wohlgemuth, Roland; Krühne, Ulrich; Gernaey, Krist; Woodley, John**

*Publication date:*  
2013

*Document Version*  
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

*Citation (APA):*  
Pereira Rosinha, I., Ringborg, R. H., Heintz, S., Tufvesson, P., Schürmann, M., Panella, L., Wohlgemuth, R., Krühne, U., Gernaey, K., & Woodley, J. (2013). *Miniaturized Experimental Toolbox for -Transaminase Technology (BIOINTENSE)*. Poster session presented at 1st International Symposium of Transaminase Biocatalysis, Stockholm, Sweden.

---

### General rights


Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



# Miniaturized Experimental Toolbox for $\omega$ -Transaminase Technology (BIOINTENSE)



Inês Rosinha<sup>1</sup>, Rolf H. Ringborg<sup>1</sup>, Søren Heintz<sup>1</sup>, Pär Tufvesson<sup>1</sup>, Martin Schürmann<sup>2</sup>, Lavinia Panella<sup>2</sup>, Roland Wohlgemuth<sup>3</sup>, Ulrich Krühne<sup>1</sup>, Krist V. Gernaey<sup>1</sup> and John M. Woodley<sup>1</sup>.

<sup>1</sup>Center for Process Engineering and Technology, Department of Chemical and Biochemical Engineering, Technical University of Denmark, DK-2800 Kgs. Lyngby, Denmark

<sup>2</sup>DSM Innovative Synthesis, 6167 RD Geleen, The Netherlands, <sup>3</sup>Research Specialties, Sigma-Aldrich, CH-9470 Buchs, Switzerland, e-mail: [shein@kt.dtu.dk](mailto:shein@kt.dtu.dk)

## Introduction:

The next generation biocatalytic processes in industry face new challenges, e.g. high concentration operation, unfavourable reaction equilibrium, complex molecule formation, minimum environmental impact, etc. [1]. Significant work is therefore required for development of the biocatalyst and process to fit commercial requirements. It is quite demanding to find the best biocatalyst and process combination to fit industrial requirements, especially with respect to the limited resource availability at an early stage of development.


BIOINTENSE, an EC FP7 funded program, has focus on developing toolboxes capable of accelerating biocatalyst and process development through the use of modular microsystem platforms. Operation at micro-scale enable better process control, low consumption of resources, fast process evaluation, as well as rapid mass and heat transfer [2, 3].

BIOINTENSE will deliver 3 types of platforms (figure 1): 1) High data content biocatalyst

screening platforms, 2) generic process development platforms operated by the plug-and-play principle, 3) production platforms for product synthesis.

The platforms will be developed for  $\omega$ -transaminase-catalysed reaction systems, scheme 1. These systems are quite interesting due to the highly unfavourable equilibrium of such reactions and the severe inhibiting effects of both substrates and products, although there are also systems enabling complete conversion. [4, 5, 6, 7].

Scheme 1: Example of reaction scheme from benzylacetone to (S)-3-amino-1-phenylbutane



## Platform 1

As a result of the theoretical process design unit operations (MUO's—Miniaturized Unit Operations) are chosen for data collection, constrained by economic assessment. The collected data will provide hard constraints for the biocatalyst performance.

## Platform 2

The target from platform 1 will be reached by development of the biocatalyst through protein engineering. The mutants will be evaluated by high content screening methods.

## Platform 3

By combining the process design and developed biocatalysts, system validation of the production platforms is performed by synthesis of the product-in-the-bottle as final evaluation.




Figure 1

## References

- [1] D. J. Pollard, J. M. Woodley, *Trends in Biotechnology*, 2006, 25, 66-73
- [2] K. Jähnisch, V. Hessel, H. Löwe, M. Baerns, *Angew. Chem. Int. Ed.*, 2004, 43, 406-446
- [3] P. L. Urban, D. M. Goodall, N. C. Bruce, *Biotech. Adv.*, 2006, 24, 42-57
- [4] P. Tufvesson, J. Lima-Ramos, J. S. Jensen, N. Al-Haque, W. Neto, J. M. Woodley, *Biotech. Bioeng.*, 2011, 108, 1479-1493
- [5] K. Drauz, H. Gröger, O. May, *Enzyme Catalysis in Organic Synthesis*, 2012, 3, 779-820
- [6] U. Schell, R. Wohlgemuth, J. M. Ward, *J. Mol. Catal. B: Enzymatic*, 2009, 59, 279-285
- [7] J. Ward, R. Wohlgemuth, *Current Organic Chemistry*, 2010, 14, 1914-1927




Figure 2

The quality of models is to a large extent determined by the number of experimental data points available (Figure 2). Conventional analytics require certain sample quantities, limiting the number of samples that can be collected. Micro-scale operations can offer solutions to these requirements.

The authors acknowledge the support of project BIOINTENSE, financed through the European Union 7<sup>th</sup> Framework Programme (Grant agreement no.: 312148)